Skip to main content

Table 3 Categorization of irAEs

From: Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

irAEs No. (%) Median days to onset Grade of irAEs, n, 1/2/3/4
Diarrhea/colitis 5 (7.7) 60.0 2/2/1/0
Hyperglycemia 2 (3.1) 398.5 0/0/2/0
Pruritus 2 (3.1) 50.0 2/0/0/0
Rash 2 (3.1) 12.0 1/1/0/0
Type 1 DM 2 (3.1) 398.5 0/2/0/0
Adrenal insufficiency 1 (1.5) 143.0 0/0/1/0
ALT increased 1 (1.5) 28.0 0/1/0/0
AST increased 1 (1.5) 28.0 0/0/1/0
Appetite loss 1 (1.5) 158.0 1/0/0/0
Hypothyroidism 1 (1.5) 167.0 1/0/0/0
Dry skin 1 (1.5) 29.0 1/0/0/0
Edema limbs 1 (1.5) 28.0 1/0/0/0
Myalgia 1 (1.5) 16.0 0/1/0/0
Peripheral motor neuropathy 1 (1.5) 3.0 0/0/1/0
Pneumonitis 1 (1.5) 32.0 0/1/0/0
QTc interval prolonged 1 (1.5) 42.0 1/0/0/0
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, DM diabetes mellitus, irAEs immune-related adverse events, QTc corrected QT
\